Business
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
U.S. demand for telehealth will soar by 64.3% in 2020 because of the COVID-19 pandemic, according to a report released by Frost & Sullivan.
Petros will be helmed by Charles S. Ryan, who currently serves as chief executive officer of Neurotrope.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
The goal is to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer.
With the COVID-19 pandemic closing physicians’ offices and causing patients to think twice about exposing themselves in healthcare settings, Neurocrine is delaying its launch of Ongentysis®.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
The company announced that one of its antibodies, STI-1499, has shown 100% inhibition of SARS-CoV-2 in laboratory tests.
Earlier this week, Sanofi’s chief executive officer Paul Hudson indicated that the U.S. would have first access to its COVID-19 vaccine because of the significant financial support it is receiving from the U.S. government.
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
A gene therapy that eliminates the need for radical cystectomies (complete removal of the bladder) in a particular, aggressive form of bladder cancer is undergoing Priority Review by the U.S. Food and Drug Administration.